Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
Authors:
Open Access
- 1 January 2020
- journal article
- editorial
- Published by Wiley in Clinical & Translational Immunology
- Vol. 9 (10)
Abstract
Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease‐19 (COVID‐19). Although placebo‐controlled, double‐blind randomised clinical trials are lacking, current data from either retrospective, case series or open‐label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID‐19 patients. See alsoShao et al.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR‐20‐COVI‐0093‐COVIMUNE)
This publication has 16 references indexed in Scilit:
- Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case seriesVirology, 2020
- Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19Journal of Infection, 2020
- Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational studyBMJ, 2020
- Anakinra for severe forms of COVID-19: a cohort studyThe Lancet Rheumatology, 2020
- Currently Available Intravenous Immunoglobulin Contains Antibodies Reacting Against Severe Acute Respiratory Syndrome Coronavirus 2 AntigensImmunotherapy, 2020
- Adjunct Immunotherapies for the Management of Severely Ill COVID-19 PatientsCell Reports Medicine, 2020
- High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019Open Forum Infectious Diseases, 2020
- IVIG-mediated effector functions in autoimmune and inflammatory diseasesInternational Immunology, 2017
- Update on the use of immunoglobulin in human disease: A review of evidenceJournal of Allergy and Clinical Immunology, 2017
- Molecular and immunological biomarkers to predict IVIg responseTrends in Molecular Medicine, 2015